Published in Mol Cell Neurosci on November 01, 2003
Alzheimer's disease: strategies for disease modification. Nat Rev Drug Discov (2010) 3.48
The beta-secretase enzyme BACE in health and Alzheimer's disease: regulation, cell biology, function, and therapeutic potential. J Neurosci (2009) 2.80
Trafficking and proteolytic processing of APP. Cold Spring Harb Perspect Med (2012) 2.56
BACE1 regulates voltage-gated sodium channels and neuronal activity. Nat Cell Biol (2007) 2.18
Alzheimer disease models and human neuropathology: similarities and differences. Acta Neuropathol (2007) 2.09
The Alzheimer's disease beta-secretase enzyme, BACE1. Mol Neurodegener (2007) 1.81
Targeting the β secretase BACE1 for Alzheimer's disease therapy. Lancet Neurol (2014) 1.76
beta-Secretase as a therapeutic target for Alzheimer's disease. Neurotherapeutics (2008) 1.74
Differential contribution of the three Aph1 genes to gamma-secretase activity in vivo. Proc Natl Acad Sci U S A (2005) 1.69
Secretome protein enrichment identifies physiological BACE1 protease substrates in neurons. EMBO J (2012) 1.61
The role of amyloid precursor protein processing by BACE1, the beta-secretase, in Alzheimer disease pathophysiology. J Biol Chem (2008) 1.57
Function, therapeutic potential and cell biology of BACE proteases: current status and future prospects. J Neurochem (2014) 1.37
Treatment strategies targeting amyloid β-protein. Cold Spring Harb Perspect Med (2012) 1.37
BACE1 inhibitor drugs in clinical trials for Alzheimer's disease. Alzheimers Res Ther (2014) 1.30
Beta-secretase inhibitor GRL-8234 rescues age-related cognitive decline in APP transgenic mice. FASEB J (2010) 1.29
BACE1 knock-outs display deficits in activity-dependent potentiation of synaptic transmission at mossy fiber to CA3 synapses in the hippocampus. J Neurosci (2008) 1.25
Transgenic models of Alzheimer's disease: learning from animals. NeuroRx (2005) 1.21
The neural cell adhesion molecules L1 and CHL1 are cleaved by BACE1 protease in vivo. J Biol Chem (2012) 1.13
The Membrane-Bound Aspartyl Protease BACE1: Molecular and Functional Properties in Alzheimer's Disease and Beyond. Front Physiol (2012) 1.09
Reduction in BACE1 decreases body weight, protects against diet-induced obesity and enhances insulin sensitivity in mice. Biochem J (2012) 1.04
Processing of the synaptic cell adhesion molecule neurexin-3beta by Alzheimer disease alpha- and gamma-secretases. J Biol Chem (2010) 1.03
Alzheimer's β-secretase (BACE1) regulates the cAMP/PKA/CREB pathway independently of β-amyloid. J Neurosci (2012) 1.02
Amyloid-β peptide: Dr. Jekyll or Mr. Hyde? J Alzheimers Dis (2013) 0.96
Cdk5 protein inhibition and Aβ42 increase BACE1 protein level in primary neurons by a post-transcriptional mechanism: implications of CDK5 as a therapeutic target for Alzheimer disease. J Biol Chem (2012) 0.92
The Basic Biology of BACE1: A Key Therapeutic Target for Alzheimer's Disease. Curr Genomics (2007) 0.90
Lessons from a BACE1 inhibitor trial: off-site but not off base. Alzheimers Dement (2014) 0.89
beta-Secretase cleavage is not required for generation of the intracellular C-terminal domain of the amyloid precursor family of proteins. FEBS J (2010) 0.89
The keystone of Alzheimer pathogenesis might be sought in Aβ physiology. Neuroscience (2015) 0.89
β-Secretase: its biology as a therapeutic target in diseases. Trends Pharmacol Sci (2013) 0.88
Antagonistic Effects of BACE1 and APH1B-γ-Secretase Control Axonal Guidance by Regulating Growth Cone Collapse. Cell Rep (2015) 0.88
Activation of protein kinase C modulates BACE1-mediated beta-secretase activity. Neurobiol Aging (2006) 0.86
β-secretase cleavage of the fly amyloid precursor protein is required for glial survival. J Neurosci (2012) 0.86
Consequences of inhibiting amyloid precursor protein processing enzymes on synaptic function and plasticity. Neural Plast (2012) 0.86
Knock-in of human BACE1 cleaves murine APP and reiterates Alzheimer-like phenotypes. J Neurosci (2014) 0.86
Mossy fiber long-term potentiation deficits in BACE1 knock-outs can be rescued by activation of alpha7 nicotinic acetylcholine receptors. J Neurosci (2010) 0.84
Neurological dysfunctions associated with altered BACE1-dependent Neuregulin-1 signaling. J Neurochem (2015) 0.81
Potential therapeutic strategies for Alzheimer's disease targeting or beyond β-amyloid: insights from clinical trials. Biomed Res Int (2014) 0.81
β-Amyloid peptides and amyloid plaques in Alzheimer's disease. Neurotherapeutics (2015) 0.80
Design and characterization of a new cell-permeant inhibitor of the beta-secretase BACE1. Br J Pharmacol (2005) 0.79
Using the zebrafish model for Alzheimer's disease research. Front Genet (2014) 0.78
Screening a series of sialyltransferases for possible BACE1 substrates. Glycoconj J (2006) 0.76
BRI2 interacts with BACE1 and regulates its cellular levels by promoting its degradation and reducing its mRNA levels. Curr Alzheimer Res (2013) 0.76
AβPP-selective BACE inhibitors (ASBI): novel class of therapeutic agents for alzheimer's disease. J Alzheimers Dis (2013) 0.76
Unfolded Protein Response and PERK Kinase as a New Therapeutic Target in the Pathogenesis of Alzheimer's Disease. Curr Med Chem (2015) 0.76
Ion channel regulation by β-secretase BACE1 - enzymatic and non-enzymatic effects beyond Alzheimer's disease. Channels (Austin) (2016) 0.75
Pharmacological applications of a novel neoepitope antibody to a modified amyloid precursor protein-derived beta-secretase product. Protein Cell (2011) 0.75
Design of Potent and Highly Selective Inhibitors for Human β-Secretase 2 (Memapsin 1), a Target for Type 2 Diabetes. Chem Sci (2016) 0.75
Genetic Deletion of the Clathrin Adaptor GGA3 Reduces Anxiety and Alters GABAergic Transmission. PLoS One (2016) 0.75
BACE1-Dependent Neuregulin-1 Signaling: An Implication for Schizophrenia. Front Mol Neurosci (2017) 0.75
Low-Frequency Repetitive Transcranial Magnetic Stimulation Ameliorates Cognitive Function and Synaptic Plasticity in APP23/PS45 Mouse Model of Alzheimer's Disease. Front Aging Neurosci (2017) 0.75
Splice variants of the Alzheimer's disease beta-secretase, BACE1. Neurogenetics (2012) 0.75
Early-onset behavioral and synaptic deficits in a mouse model of Alzheimer's disease. Proc Natl Acad Sci U S A (2006) 3.61
Rapamycin alleviates toxicity of different aggregate-prone proteins. Hum Mol Genet (2005) 3.45
Loss of retrograde endocannabinoid signaling and reduced adult neurogenesis in diacylglycerol lipase knock-out mice. J Neurosci (2010) 2.78
The serine protease Omi/HtrA2 regulates apoptosis by binding XIAP through a reaper-like motif. J Biol Chem (2001) 2.47
Phospho-dependent functional modulation of GABA(B) receptors by the metabolic sensor AMP-dependent protein kinase. Neuron (2007) 2.38
Activation of estrogen receptor-beta regulates hippocampal synaptic plasticity and improves memory. Nat Neurosci (2008) 2.29
Neuroprotective role of the Reaper-related serine protease HtrA2/Omi revealed by targeted deletion in mice. Mol Cell Biol (2004) 2.15
Acute gamma-secretase inhibition improves contextual fear conditioning in the Tg2576 mouse model of Alzheimer's disease. J Neurosci (2005) 2.05
Exclusively targeting beta-secretase to lipid rafts by GPI-anchor addition up-regulates beta-site processing of the amyloid precursor protein. Proc Natl Acad Sci U S A (2003) 2.03
mRNA distribution analysis of human TRPC family in CNS and peripheral tissues. Brain Res Mol Brain Res (2002) 1.98
Impact of apolipoprotein E (ApoE) polymorphism on brain ApoE levels. J Neurosci (2008) 1.92
The clustering of GABA(A) receptor subtypes at inhibitory synapses is facilitated via the direct binding of receptor alpha 2 subunits to gephyrin. J Neurosci (2008) 1.83
Myocardial protection from ischemia/reperfusion injury by targeted deletion of matrix metalloproteinase-9. Cardiovasc Res (2002) 1.83
Caspase-6 gene disruption reveals a requirement for lamin A cleavage in apoptotic chromatin condensation. EMBO J (2002) 1.82
Monoacylglycerol lipase activity is a critical modulator of the tone and integrity of the endocannabinoid system. Mol Pharmacol (2010) 1.81
The basal proton conductance of skeletal muscle mitochondria from transgenic mice overexpressing or lacking uncoupling protein-3. J Biol Chem (2001) 1.69
Neuronal membrane cholesterol loss enhances amyloid peptide generation. J Cell Biol (2004) 1.66
The LXR agonist TO901317 selectively lowers hippocampal Abeta42 and improves memory in the Tg2576 mouse model of Alzheimer's disease. Mol Cell Neurosci (2007) 1.66
Phospho-dependent binding of the clathrin AP2 adaptor complex to GABAA receptors regulates the efficacy of inhibitory synaptic transmission. Proc Natl Acad Sci U S A (2005) 1.56
Begacestat (GSI-953): a novel, selective thiophene sulfonamide inhibitor of amyloid precursor protein gamma-secretase for the treatment of Alzheimer's disease. J Pharmacol Exp Ther (2009) 1.51
Activity-dependent ubiquitination of GABA(A) receptors regulates their accumulation at synaptic sites. J Neurosci (2007) 1.49
Phosphorylation and chronic agonist treatment atypically modulate GABAB receptor cell surface stability. J Biol Chem (2004) 1.40
Treatment strategies targeting amyloid β-protein. Cold Spring Harb Perspect Med (2012) 1.37
GSK189254, a novel H3 receptor antagonist that binds to histamine H3 receptors in Alzheimer's disease brain and improves cognitive performance in preclinical models. J Pharmacol Exp Ther (2007) 1.30
A diacylglycerol lipase-CB2 cannabinoid pathway regulates adult subventricular zone neurogenesis in an age-dependent manner. Mol Cell Neurosci (2008) 1.30
Cognitive correlates of Abeta deposition in male and female mice bearing amyloid precursor protein and presenilin-1 mutant transgenes. Brain Res (2004) 1.27
Missing steps in the STAIR case: a Translational Medicine perspective on the development of NXY-059 for treatment of acute ischemic stroke. J Cereb Blood Flow Metab (2007) 1.26
Pittsburgh compound B (11C-PIB) and fluorodeoxyglucose (18 F-FDG) PET in patients with Alzheimer disease, mild cognitive impairment, and healthy controls. J Geriatr Psychiatry Neurol (2010) 1.24
Binding of rapamycin analogs to calcium channels and FKBP52 contributes to their neuroprotective activities. Proc Natl Acad Sci U S A (2007) 1.23
Discovery of begacestat, a Notch-1-sparing gamma-secretase inhibitor for the treatment of Alzheimer's disease. J Med Chem (2008) 1.22
Oral administration of a potent and selective non-peptidic BACE-1 inhibitor decreases beta-cleavage of amyloid precursor protein and amyloid-beta production in vivo. J Neurochem (2007) 1.20
Cloning and functional expression of human short TRP7, a candidate protein for store-operated Ca2+ influx. J Biol Chem (2002) 1.19
Function and distribution of circulating human PCSK9 expressed extrahepatically in transgenic mice. J Lipid Res (2008) 1.18
Prolonged activation of NMDA receptors promotes dephosphorylation and alters postendocytic sorting of GABAB receptors. Proc Natl Acad Sci U S A (2010) 1.14
Myostatin inhibition slows muscle atrophy in rodent models of amyotrophic lateral sclerosis. Neurobiol Dis (2006) 1.12
Marlin-1, a novel RNA-binding protein associates with GABA receptors. J Biol Chem (2004) 1.12
Enhanced clearance of Abeta in brain by sustaining the plasmin proteolysis cascade. Proc Natl Acad Sci U S A (2008) 1.12
Receptor and behavioral pharmacology of WAY-267464, a non-peptide oxytocin receptor agonist. Neuropharmacology (2009) 1.12
The availability of surface GABA B receptors is independent of gamma-aminobutyric acid but controlled by glutamate in central neurons. J Biol Chem (2008) 1.12
The structure of the Lingo-1 ectodomain, a module implicated in central nervous system repair inhibition. J Biol Chem (2006) 1.11
Innovative approaches for the development of antidepressant drugs: current and future strategies. NeuroRx (2005) 1.10
alpha7 and non-alpha7 nicotinic acetylcholine receptors modulate dopamine release in vitro and in vivo in the rat prefrontal cortex. Eur J Neurosci (2009) 1.10
Non-cognitive behaviours in an APP/PS1 transgenic model of Alzheimer's disease. Behav Brain Res (2007) 1.09
Raft disorganization leads to reduced plasmin activity in Alzheimer's disease brains. EMBO Rep (2003) 1.09
Unravelling the unusual signalling properties of the GABA(B) receptor. Biochem Pharmacol (2004) 1.09
Molecular and pharmacological characterization of genes encoding urotensin-II peptides and their cognate G-protein-coupled receptors from the mouse and monkey. Br J Pharmacol (2002) 1.07
The BTBR mouse model of autism spectrum disorders has learning and attentional impairments and alterations in acetylcholine and kynurenic acid in prefrontal cortex. PLoS One (2013) 1.06
p38alpha stress-activated protein kinase phosphorylates neurofilaments and is associated with neurofilament pathology in amyotrophic lateral sclerosis. Mol Cell Neurosci (2004) 1.04
Effects of N-acetylaspartylglutamate (NAAG) at group II mGluRs and NMDAR. Neuropharmacology (2009) 1.04
Reduction in BACE1 decreases body weight, protects against diet-induced obesity and enhances insulin sensitivity in mice. Biochem J (2012) 1.04
WAY-163909 [(7bR,10aR)-1,2,3,4,8,9,10,10a-octahydro-7bH-cyclopenta-[b][1,4]diazepino[6,7,1hi]indole]: A novel 5-hydroxytryptamine 2C receptor-selective agonist with preclinical antipsychotic-like activity. J Pharmacol Exp Ther (2006) 1.03
BACE1 cytoplasmic domain interacts with the copper chaperone for superoxide dismutase-1 and binds copper. J Biol Chem (2005) 1.02
Analysis of serial magnetic resonance images of mouse brains using image registration. Neuroimage (2008) 1.02
Altered intrinsic neuronal excitability and reduced Na+ currents in a mouse model of Alzheimer's disease. Neurobiol Aging (2011) 1.02
Neuropharmacological profile of novel and selective 5-HT6 receptor agonists: WAY-181187 and WAY-208466. Neuropsychopharmacology (2007) 1.02
A simultaneous ERP/fMRI investigation of the P300 aging effect. Neurobiol Aging (2012) 1.01
Differentiating antidepressants of the future: efficacy and safety. Pharmacol Ther (2006) 1.01
SB-399885 is a potent, selective 5-HT6 receptor antagonist with cognitive enhancing properties in aged rat water maze and novel object recognition models. Eur J Pharmacol (2006) 1.01
Methamphetamine-evoked depression of GABA(B) receptor signaling in GABA neurons of the VTA. Neuron (2012) 1.01
Bombesin receptors as a novel anti-anxiety therapeutic target: BB1 receptor actions on anxiety through alterations of serotonin activity. J Neurosci (2006) 1.00
Effects of pan- and subtype-selective N-methyl-D-aspartate receptor antagonists on cortical spreading depression in the rat: therapeutic potential for migraine. J Pharmacol Exp Ther (2007) 0.99
Multiple motifs regulate the trafficking of GABA(B) receptors at distinct checkpoints within the secretory pathway. Mol Cell Neurosci (2005) 0.99
Protection against Aβ-mediated rapid disruption of synaptic plasticity and memory by memantine. Neurobiol Aging (2009) 0.99
Attenuation of amphetamine-induced activity by the non-selective muscarinic receptor agonist, xanomeline, is absent in muscarinic M4 receptor knockout mice and attenuated in muscarinic M1 receptor knockout mice. Eur J Pharmacol (2008) 0.99
Ganglioside inhibition of neurite outgrowth requires Nogo receptor function: identification of interaction sites and development of novel antagonists. J Biol Chem (2008) 0.98
GABA(B) receptor activation triggers BDNF release and promotes the maturation of GABAergic synapses. J Neurosci (2009) 0.97
The development of stroke therapeutics: promising mechanisms and translational challenges. Neuropharmacology (2008) 0.96
Circadian and dark-pulse activation of orexin/hypocretin neurons. Mol Brain (2008) 0.96
GABA(A) receptor membrane trafficking regulates spine maturity. Proc Natl Acad Sci U S A (2009) 0.96
Structural correlates of antibodies associated with acute reversal of amyloid beta-related behavioral deficits in a mouse model of Alzheimer disease. J Biol Chem (2009) 0.94
High-performance liquid chromatography/tandem mass spectrometry assay for the rapid high sensitivity measurement of basal acetylcholine from microdialysates. J Neurosci Methods (2002) 0.94
Neurochemical changes in LPA1 receptor deficient mice--a putative model of schizophrenia. Neurochem Res (2005) 0.94
SB-649915-B, a novel 5-HT1A/B autoreceptor antagonist and serotonin reuptake inhibitor, is anxiolytic and displays fast onset activity in the rat high light social interaction test. Neuropsychopharmacology (2007) 0.93
UDP-glucose modulates gastric function through P2Y14 receptor-dependent and -independent mechanisms. Am J Physiol Gastrointest Liver Physiol (2009) 0.93
The 5-HT(6) receptor antagonist SB-271046 reverses scopolamine-disrupted consolidation of a passive avoidance task and ameliorates spatial task deficits in aged rats. Neuropsychopharmacology (2004) 0.93
Characterization of the ectodomain shedding of the beta-site amyloid precursor protein-cleaving enzyme 1 (BACE1). J Biol Chem (2003) 0.93
Neurochemical evaluation of the novel 5-HT1A receptor partial agonist/serotonin reuptake inhibitor, vilazodone. Eur J Pharmacol (2005) 0.92
Second generation of hydroxyethylamine BACE-1 inhibitors: optimizing potency and oral bioavailability. J Med Chem (2008) 0.92
Comparison of the effects of antidepressants on norepinephrine and serotonin concentrations in the rat frontal cortex: an in-vivo microdialysis study. J Psychopharmacol (2002) 0.92
ADAM9 inhibition increases membrane activity of ADAM10 and controls α-secretase processing of amyloid precursor protein. J Biol Chem (2011) 0.92
Rosiglitazone attenuates the age-related changes in astrocytosis and the deficit in LTP. Neurobiol Aging (2010) 0.92
Longitudinal regional brain volume changes quantified in normal aging and Alzheimer's APP x PS1 mice using MRI. Brain Res (2009) 0.91
Postsynaptic GABAB receptor activity regulates excitatory neuronal architecture and spatial memory. J Neurosci (2014) 0.90
Evidence for antimanic efficacy of glycogen synthase kinase-3 (GSK3) inhibitors in a strain-specific model of acute mania. Int J Neuropsychopharmacol (2011) 0.90
Sodium channel cleavage is associated with aberrant neuronal activity and cognitive deficits in a mouse model of Alzheimer's disease. J Neurosci (2013) 0.90
Gamma-hydroxybutyric acid (GHB) and gamma-aminobutyric acidB receptor (GABABR) binding sites are distinctive from one another: molecular evidence. Neuropharmacology (2004) 0.90
Functional modulation of GABAB receptors by protein kinases and receptor trafficking. Adv Pharmacol (2010) 0.90
Changes in resting connectivity with age: a simultaneous electroencephalogram and functional magnetic resonance imaging investigation. Neurobiol Aging (2013) 0.89
Caspase-7 gene disruption reveals an involvement of the enzyme during the early stages of apoptosis. J Biol Chem (2003) 0.89
Cyclin-dependent kinase-5/p35 phosphorylates Presenilin 1 to regulate carboxy-terminal fragment stability. Mol Cell Neurosci (2002) 0.89